Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 17 Issue 3, March 1999

Structure of an engineered dimeric human ribonuclease (foreground) which has been altered to both facilitate targetting to cancer cells and to render it insensitive to its natural cytosolic inhibitor (shown in background). For more details, see Suzuki et al. p265 and Wagner and Lipovsek, p227 Illustration by Ken Eward (BioGrafx,Mount Vernon, Ohio).

Editorial

Top of page ⤴

Commentary

Top of page ⤴

Correspondence

Top of page ⤴

Erratum

Top of page ⤴

Business and Regulatory News

Top of page ⤴

Research News

Top of page ⤴

This Month in Biotechnology

Top of page ⤴

Analysis

Top of page ⤴

Research News and Views

Top of page ⤴

Feature

Top of page ⤴

Research Article

Top of page ⤴

Patents

Top of page ⤴

In the Laboratory

Top of page ⤴

Book Review

Top of page ⤴

Internet

    • Stacey McCann
    Internet
Top of page ⤴

People

Top of page ⤴

New Products

Top of page ⤴

Industry Trends

Top of page ⤴

Search

Quick links